PATENT CLAIM ANALYSIS

Application Number: 15863159
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "093210"]

Abstract:
The present invention provides for modified natural killer (NK) cells that are resistant to TGF-β stimulation due to suppressed Smad3 activity in these cells. Also provided are compositions comprising these modified NK cells, as well as methods of treating cancer by using the cells.

Claim (Index 13):
The method of  claim 12 , wherein the injection is subcutaneous, intramuscular, intravenous, intraperitoneal, or intratumoral injection.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 86.0
- Lexical Diversity: 1.25641
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14123202', '14815721', '15690092', '12973823', '15319660']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6693255217079273
- 35 USC 102 Novelty (BERT): 0.5133235057117269
- Combined Prediction Score: 0.6537253201083072
- Mean Citation Score: 241.417206
- Max Citation Score: 248.55464
- Similarity Product: 167.40301708165168

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test